CA3064975A1 - Nouveaux inhibiteurs de map4k1 - Google Patents

Nouveaux inhibiteurs de map4k1 Download PDF

Info

Publication number
CA3064975A1
CA3064975A1 CA3064975A CA3064975A CA3064975A1 CA 3064975 A1 CA3064975 A1 CA 3064975A1 CA 3064975 A CA3064975 A CA 3064975A CA 3064975 A CA3064975 A CA 3064975A CA 3064975 A1 CA3064975 A1 CA 3064975A1
Authority
CA
Canada
Prior art keywords
phenyl
oxy
trifluoromethyl
oxazin
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3064975A
Other languages
English (en)
Inventor
Vinod Patel
Venkateshwar REDDY
Laxmikant Atmaram Gharat
Sachin Sundarial Chaudhari
Sanjib Das
Ranganadh VELGALETI
Daisy Manish Shah
Malini Bajpai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ichnos Sciences SA
Original Assignee
Glenmark Pharmaceuticals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glenmark Pharmaceuticals SA filed Critical Glenmark Pharmaceuticals SA
Publication of CA3064975A1 publication Critical patent/CA3064975A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

L'invention concerne de nouveaux inhibiteurs de MAP4K1 (HPK1) utiles pour le traitement de maladies ou de troubles caractérisés par un dérèglement des voies de transduction de signal associées à l'activation MAPK, y compris des maladies hyperprolifératives, des maladies du dysfonctionnement du système immunitaire, des troubles inflammatoires, des maladies neurologiques et des maladies cardiovasculaires. L'invention concerne en outre des compositions pharmaceutiques comprenant lesdits inhibiteurs et des méthodes de traitement desdites maladies et troubles. Les inhibiteurs de l'invention sont représentés par la formule (I), dans laquelle les définitions pour A, D, E, F, R5, R6, R7, Z, le cycle Q, n, x et y sont tels que définis dans la description.
CA3064975A 2017-05-26 2018-05-28 Nouveaux inhibiteurs de map4k1 Abandoned CA3064975A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762511455P 2017-05-26 2017-05-26
US62/511,455 2017-05-26
US201762544531P 2017-08-11 2017-08-11
US62/544,531 2017-08-11
PCT/EP2018/063957 WO2018215668A1 (fr) 2017-05-26 2018-05-28 Nouveaux inhibiteurs de map4k1

Publications (1)

Publication Number Publication Date
CA3064975A1 true CA3064975A1 (fr) 2018-11-29

Family

ID=62492619

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3064975A Abandoned CA3064975A1 (fr) 2017-05-26 2018-05-28 Nouveaux inhibiteurs de map4k1

Country Status (10)

Country Link
EP (1) EP3630778A1 (fr)
JP (1) JP2021506735A (fr)
KR (1) KR20200011965A (fr)
CN (1) CN112601752A (fr)
AU (1) AU2018272986A1 (fr)
CA (1) CA3064975A1 (fr)
EA (1) EA201992584A1 (fr)
IL (1) IL270844A (fr)
MX (1) MX2019013922A (fr)
WO (1) WO2018215668A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021005047A (es) 2018-10-31 2021-09-08 Gilead Sciences Inc Compuestos de 6-azabenzimidazol sustituidos como inhibidores de hpk1.
WO2020092528A1 (fr) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Composés 6-azabenzimidazole substitués ayant une activité inhibitrice de hpk1
EP3894406A1 (fr) 2018-12-11 2021-10-20 Bayer Aktiengesellschaft Dérivés de pyrrolopyridine substitués
MA55478A (fr) 2019-03-26 2022-02-09 Janssen Pharmaceutica Nv Inhibiteurs bicycliques de hpk1
WO2020193511A1 (fr) 2019-03-26 2020-10-01 Janssen Pharmaceutica Nv Inhibiteurs de hpk1
EP3972695A1 (fr) 2019-05-23 2022-03-30 Gilead Sciences, Inc. Exo-méthylène-oxindoles substitués qui sont des inhibiteurs de hpk1/map4k1
KR20220038696A (ko) * 2019-07-19 2022-03-29 아나제네시스 바이오테크놀로지스 에스.에이.에스. 폴리방향족 우레아 유도체 및 근육 질환 치료에서의 이들의 용도
WO2021249913A1 (fr) 2020-06-09 2021-12-16 Bayer Aktiengesellschaft Dérivés de 2'-(quinolin-3-yl)-5',6'-dihydrospiro[azétidine-3,4'-pyrrolo[1,2-b]pyrazole]-1-carboxylate et des composés apparentés servant d'inhibiteurs de map4k1 (hpk1) pour le traitement du cancer
MX2023000519A (es) 2020-07-15 2023-02-13 Chiesi Farm Spa Derivados de pirido-oxazina-amino como inhibidores de alk5.
CN112225748B (zh) * 2020-10-20 2021-11-30 四川大学华西医院 一种具有flt3激酶抑制活性的小分子化合物及其应用
CN114539065B (zh) * 2020-11-25 2023-07-25 帕潘纳(北京)科技有限公司 制备4-硝基-2-三氟甲基苯乙酮的方法
WO2022136221A1 (fr) 2020-12-23 2022-06-30 Chiesi Farmaceutici S.P.A. Dérivés de pyrido-oxazine utilisés comme inhibiteurs d'alk5
EP4029501A1 (fr) 2021-01-19 2022-07-20 Anagenesis Biotechnologies Combinaison de dérivés polyaromatiques de l'urée et d'inhibiteur glucocorticoïde ou hdac pour le traitement de maladies ou d'affections associées aux cellules musculaires et/ou aux cellules satellites
WO2022167627A1 (fr) 2021-02-05 2022-08-11 Bayer Aktiengesellschaft Inhibiteurs de map4k1
JP2024513227A (ja) 2021-04-05 2024-03-22 ハリア・セラピューティクス・インコーポレイテッド Ｎｅｋ７阻害剤
WO2022226182A1 (fr) 2021-04-22 2022-10-27 Halia Therapeutics, Inc. Inhibiteurs de nek7
CN113603635B (zh) * 2021-10-08 2021-12-24 湖南速博生物技术有限公司 一种芳香族二元羧酸酯水解脱羧的方法
EP4289427A1 (fr) * 2022-06-10 2023-12-13 Anagenesis Biotechnologies Dihydro[1,8]naphthyridin-7-one et pyrido[3,2-b][1,4]oxazin-3-one pour une utilisation dans le traitement du cancer, et des métastases en particulier.
WO2024059200A1 (fr) 2022-09-14 2024-03-21 Halia Therapeutics, Inc. Inhibiteurs de nek7
CN117049938A (zh) * 2023-06-20 2023-11-14 山东轩德医药科技有限公司 一种6-溴-2,3-二氟甲苯的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE355275T1 (de) * 2000-10-20 2006-03-15 Eisai R&D Man Co Ltd Stickstoff-enthaltende aromatische ringverbindungen zur behandlung von tumorerkrankungen
CN102573994B (zh) * 2009-08-06 2015-06-24 默克专利有限公司 双环脲化合物
US9283225B2 (en) * 2011-08-10 2016-03-15 Merck Patent Gmbh Pyrido-pyrimidine derivatives
TWI520962B (zh) * 2012-06-29 2016-02-11 As the c-Met tyrosine kinase inhibitors novel fused pyridine derivatives

Also Published As

Publication number Publication date
AU2018272986A1 (en) 2019-12-12
WO2018215668A1 (fr) 2018-11-29
CN112601752A (zh) 2021-04-02
MX2019013922A (es) 2020-08-17
EA201992584A1 (ru) 2020-06-18
EP3630778A1 (fr) 2020-04-08
JP2021506735A (ja) 2021-02-22
KR20200011965A (ko) 2020-02-04
IL270844A (en) 2020-01-30

Similar Documents

Publication Publication Date Title
CA3064975A1 (fr) Nouveaux inhibiteurs de map4k1
JP6689805B2 (ja) カテプシンｃの置換２−アザ−ビシクロ［２．２．１］ヘプタン−３−カルボン酸（ベンジル−シアノ−メチル）−アミド阻害剤
CA2969090C (fr) Composes triazolopyrimidine et leurs utilisations
CA2779105C (fr) Inhibiteurs de kinases
US11053197B2 (en) Carbazole derivatives
US10730853B2 (en) Compounds as neuronal histamine receptor-3 antagonists and uses thereof
US20220119363A1 (en) 2-amino-n-phenyl-nicotinamides as nav1.8 inhibitors
EP2828259B1 (fr) Composés de pyridopyrimidine substituée et leur utilisation comme inhibiteurs de flt3
CA2932008A1 (fr) Derives benzimidazoles tricycliques condenses comme modulateurs de l'activite du tnf
CA3204823A1 (fr) Inhibiteurs de prmts
US10336755B2 (en) Fused pyrazole derivatives, preparation method thereof, and use thereof in treatment of cancers, inflammation and immune diseases
EP3414234A1 (fr) Inhibiteurs de la tyrosine kinase de bruton
BR112014022271B1 (pt) Compostos com base em imidazo[1,2-b]piridazina, composições compreendendo-os, e usos dos mesmos
WO2012000632A1 (fr) Pyrazoloquinoléines
EP2780332A1 (fr) Morpholinylbenzotriazines destinées à être utilisées en oncothérapie
CN111315734B (zh) 作为食欲素受体拮抗剂的经取代的2-氮杂双环[3.1.1]庚烷和2-氮杂双环[3.2.1]辛烷衍生物
KR20190067788A (ko) Pde2 억제제로서의 [1,2,4]트리아졸로[1,5-a]피리미딘 화합물
CN111518100A (zh) 环丙烯并苯并呋喃取代的氮杂芳基化合物及其应用
CN116514846A (zh) 杂环类衍生物、其制备方法及其医药上的用途
JP2023545219A (ja) Ｂｃｒ－ａｂｌチロシンキナーゼの阻害のための７－アザインドール化合物
WO2017046603A1 (fr) Composés antibactériens et nouvelles utilisations de ceux-ci
WO2022170164A1 (fr) Sulfonamides ayant des activités d'inhibition de l'egfr et leur utilisation
WO2023224998A1 (fr) Inhibiteurs de parg
CN116041369A (zh) 嘧啶并环类衍生物、其制备方法及其在医药上的用途

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20221129

FZDE Discontinued

Effective date: 20221129